吉西他滨联合顺铂治疗晚期非小细胞肺癌临床观察

目的:观察吉西他滨联合顺铂(GP方案)治疗晚期非小细胞肺癌的临床疗效和不良反应。方法:吉西他滨1000～1250mg/m2,30min内滴完,第1、8天给药,顺铂70mg/m2,静滴,第8天吉西他滨后给药,21天为1周期。分别化疗2～6周期后按WHO标准评价疗效和不良反应。结果:入组30例均可评价疗效,部分缓解(PR)13例,稳定(SD)14例,进展(PD)3例,近期有效率43.3%,中位疾病进展时间(TTP)为6.2个月。1年生存率60.0%,中位生存期(MST)13.5个月。主要不良反应为骨髓抑制及恶心呕吐。结论:GP方案治疗晚期非小细胞肺癌疗效较好,不良反应轻,多数患者耐受良好,值得推广应用。

Gemcitabine combined with cisplatin regimen in patients with advanced none small cell lung cancer

Objective: To evaluate the efficacy and toxicity of gemcitabine combined with cisplatin (GP) regimen in patients with advanced none small cell lung cancer(NSCLC). Methods: Gemcitabine 1 000-1 250 mg/m2 iv 30 min, d1,8 and cisplatin 70 mg/m2 iv d8 after gemcitabine, and repeated every 21 days. Results: All 30 cases were available for objective response: PR 13 cases, SD 14 cases and PD 3 cases. The overall response rates (ORR) was 43.3%, 1-year-survival rate was 60.0%, the mTTP and mST was 6.2 m and 13.5 m respectively. The main toxicities were bone marrow suppression and nausea/vomiting. Conclusion: GP regimen is a high response regimen for advanced NSCLC with well-tolerated toxicity, which can be practised safely.